

**American College of Radiology
ACR Appropriateness Criteria®**

Clinical Condition: Renal Cell Carcinoma Staging

Radiologic Procedure	Rating	Comments	RRL*
CT abdomen without and with IV contrast	9	This procedure is complementary to x-ray chest.	☼☼☼☼
X-ray chest	8	This procedure is complementary to CT.	☼
MRI abdomen without and with IV contrast	8	This procedure is an alternative to CT.	O
CT abdomen with IV contrast	7	This procedure is an alternative to CT without and with contrast.	☼☼☼
CT chest without IV contrast	6		☼☼☼
CT chest with IV contrast	6		☼☼☼
CT abdomen and pelvis with IV contrast	5		☼☼☼
CT abdomen and pelvis without and with IV contrast	5	This procedure may be appropriate but there was disagreement among panel members on the appropriateness rating as defined by the panel's median rating.	☼☼☼☼
MRI abdomen without IV contrast	5		O
Tc-99m bone scan whole body	5		☼☼☼
MRI head without and with IV contrast	4		O
CT head with IV contrast	4		☼☼☼
CT abdomen and pelvis without IV contrast	3		☼☼☼
CT chest without and with IV contrast	3		☼☼☼
MRI head without IV contrast	3		O
CT head without IV contrast	3		☼☼☼
CT head without and with IV contrast	3		☼☼☼
US abdomen	3		O
FDG-PET/CT skull base to mid-thigh	3		☼☼☼☼
CT abdomen without IV contrast	2		☼☼☼
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			*Relative Radiation Level

RENAL CELL CARCINOMA STAGING

Expert Panel on Urologic Imaging: Raghunandan Vikram, MD¹; Michael D. Beland, MD²; M. Donald Blaurock, MD, PhD³; Courtney Coursey Moreno, MD⁴; John L. Gore, MD⁵; Howard J. Harvin, MD⁶; Marta E. Heilbrun, MD⁷; Stanley L. Liauw, MD⁸; Paul L. Nguyen, MD⁹; Paul Nikolaidis, MD¹⁰; Glenn M. Preminger, MD¹¹; Andrei S. Purysko, MD¹²; Steven S. Raman, MD¹³; Myles T. Taffel, MD¹⁴; Zhen J. Wang, MD¹⁵; Robert M. Weinfeld, MD¹⁶; Erick M. Remer, MD¹⁷; Mark E. Lockhart, MD, MPH.¹⁸

Summary of Literature Review

Introduction/Background

Renal cell carcinoma (RCC) accounts for 2%–3% of all visceral malignancies. It is estimated that approximately 61,560 new cases of RCC are diagnosed per year in the United States, resulting in approximately 14,080 deaths [1] due to cancers of the kidney and renal pelvis. The incidence of RCC appears to be increasing in the United States over the past decade [2]. The incidence in men is 1.6 times greater than in women. Metastatic disease at presentation varies with the patient series but typically occurs in about 1 in 10 patients [3,4]. The most common sites of distant metastases, in descending order, are the lungs, bone, retroperitoneal and mediastinal nodes, liver, brain, or in multiple sites [5,6].

The TNM staging system developed by the American Joint Committee on Cancer (AJCC) is now used almost universally and allows determination of prognosis [7-9].

Tumor size is critical to staging RCC for tumors confined to the kidney. In patients with T1 stage classification of RCC, there is an overall improved survival in patients with tumors <4 cm compared with those whose tumors measure 4–7 cm [7]. In a large study evaluating 47,909 cases from the National Cancer Database, patients with tumors <4 cm in diameter had a 75% 5-year survival rate, whereas tumors >10 cm in diameter yielded a median survival rate of 47.5% at 5 years [10].

Extrarenal tumor extension, such as infiltration into the perinephric or renal sinus fat and venous infiltration, is also a significant prognostic factor [11]. Hence, tumors with these characteristics are assigned stages of T3 and above. Prognosis is related to several other factors, including the tumor subtype, the stage, and the nuclear grade. Several prognostic nomograms based on staging information at the time of diagnosis have been proposed [12-15]. These models are valuable not only in patient counseling but also in risk stratification, patient selection for trials, and formulating follow-up strategies. Furthermore, recent advances in whole-genome sequencing have revealed specific genetic mutations that are associated with poor prognosis [16-18]. Future refinements of these models will probably take into consideration these genomic characteristics and may be sufficiently flexible to allow widening treatment options. Although incidentally discovered small tumors have a much better prognosis than symptomatic tumors, nonaggressive biologic behavior cannot be assumed. Klatte et al [19] showed that 7% of patients with primary tumors <4 cm had metastatic disease at presentation in a series of 1067 patients. Locally aggressive stages (pT3a and above) have been reported in 5.6% to 8% of patients with RCCs <4 cm [20-22].

Overview of Imaging Modalities

Computed Tomography

Computed tomography (CT) is a noninvasive imaging modality that uses ionizing radiation to characterize renal masses. Use of iodinated contrast material significantly improves the ability to characterize and stage the primary tumor and nodal and distant metastases. In general, 100–150 mL of iodinated intravenous (IV) contrast medium is used, with a flow rate of 2–3 mL/s. A noncontrast scan followed by a contrast-enhanced scan improves detection

¹Principal Author, University of Texas MD Anderson Cancer Center, Houston, Texas. ²Rhode Island Hospital, Providence, Rhode Island. ³Albert Einstein College of Medicine, Bronx, New York, Society of Nuclear Medicine and Molecular Imaging. ⁴Emory University Hospital, Atlanta, Georgia. ⁵University of Washington, Seattle, Washington, American Urological Association. ⁶Scottsdale Medical Imaging, Scottsdale, Arizona. ⁷University of Utah, Salt Lake City, Utah. ⁸The University of Chicago Medical Center, Chicago, Illinois. ⁹Brigham and Women's Hospital, Boston, Massachusetts. ¹⁰Northwestern University, Chicago, Illinois. ¹¹Duke University Medical Center, Durham, North Carolina, American Urological Association. ¹²Cleveland Clinic Imaging Institute, Cleveland, Ohio. ¹³University of California Los Angeles Medical Center, Los Angeles, California. ¹⁴George Washington University Hospital, Washington, District of Columbia. ¹⁵University of California San Francisco School of Medicine, San Francisco, California. ¹⁶Oakland University William Beaumont School of Medicine, Troy, Michigan. ¹⁷Specialty Chair, Cleveland Clinic, Cleveland, Ohio. ¹⁸Panel Chair, University of Alabama at Birmingham, Birmingham, Alabama.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org

of small lesions in the kidney. Lack of soft-tissue contrast limits the sensitivity of CT scanning without IV contrast as a stand-alone examination.

Chest CT is useful to detect small pulmonary metastases and metastatic mediastinal lymph nodes. Use of IV contrast does not improve detection of intrathoracic metastasis.

CT scanning of the brain may be useful in detecting brain metastasis. Noncontrast CT scanning of the brain may not be effective in detecting lesions that are small or lack mass effect or significant vasogenic edema. Use of contrast increases the accuracy of CT scans of the brain.

Magnetic Resonance Imaging

MRI provides excellent soft-tissue contrast resolution and provides radiation-free multiplanar anatomic evaluation of the abdominal organs. MRI is generally used when optimal CT cannot be performed, as in the case of pregnancy or severe allergy to iodinated contrast medium. MRI is also useful in instances where there is equivocal contrast enhancement on CT or in instances of hemorrhagic lesions. MRI has similar reported overall staging accuracies compared with CT.

A MRI protocol for renal mass evaluation should include T2-weighted images, in- and opposed-phase T1-weighted gradient echo images to detect intravoxel fat, and dynamic contrast-enhanced 3-D T1-weighted gradient echo images in arterial, nephrographic, and excretory phases. Due to its superior contrast resolution, MRI of the brain is very useful in detecting brain metastasis and for detecting meningeal tumor seeding. Compared to CT, MRI is useful in detecting smaller lesions and lesions adjacent to the bones [23]. In one study, approximately 20% of patients who demonstrated a single lesion on CT demonstrated multiple lesions on MRI [24].

Chest Radiography

Chest radiography uses ionizing radiation and is useful as a screening tool to detect pulmonary metastasis. Small pulmonary metastases are easily missed on chest radiographs. In high-risk patients, a chest CT is preferred.

Ultrasonography

Ultrasound (US) is an imaging modality free of ionizing radiation. US can be useful in differentiating solid and cystic renal masses. However, US is operator dependent and is challenging in obese patients who provide poor acoustic windows. Some of the challenges in the use of US may be related to incomplete visualization of the mass, acoustic shadowing from partially calcified cysts or masses, variability in echogenicity of hemorrhagic cysts, and poor sensitivity in diagnosing isoechoic small renal tumors. Hence, US is seldom used for local staging of RCC other than for clarification of potentially cystic tumors [25].

Bone Scans

Tc-99m methylene diphosphonate bone scans provide a survey of the entire skeleton to detect bone metastases. Bone scans involve injection of a radioisotope and use ionizing radiation. Bone scans are nonspecific in determining the cause of increased tracer uptake, particularly in solitary lesions, and may occasionally require an accompanying radiograph or cross-sectional imaging to further characterize the lesion. When available, single-photon emission computed tomography fused with CT can be utilized to provide detailed anatomic localization of the abnormal radiotracer uptake and further improve the characterization of the nature of the abnormality [26]. They also have poor spatial resolution and contrast resolution. However, the ability to survey the entire skeleton at a relatively low cost and wide availability make it a useful tool in initial screening for bone metastasis.

Arteriography

Fluoroscopy and radiography are used while performing renal arteriography after inserting a catheter into the renal artery or the aorta for injection of contrast. It is an invasive procedure and is performed when therapeutic interventions at the same setting, such as embolization of the tumor, are planned. Diagnostic arteriography is rarely performed as a stand-alone procedure.

Fluorine-18-2-fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography

Positron emission tomography (PET)/CT sequentially acquires PET scans and a CT scan, usually in a single system wherein both scanners are fitted into a single gantry. This enables the ability to provide coregistered images of both PET and CT scans. The most widely used tracer for PET scanning is fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG), which is a positron emitter. PET/CT scanners involve exposure to ionizing radiation. Use of PET/CT is controversial in renal cell carcinoma. PET/CT appears to have a better sensitivity for detecting distant metastasis than for detecting and staging RCC in the kidney [27-30]. PET/CT with 18F-sodium fluoride

(NaF) has been shown to be more sensitive in detecting bone metastasis. NaF PET/CT had the greatest impact in initial staging and in monitoring of treatment in patients with bony metastasis. Its role in staging and metastatic workup in RCC is yet to be defined [31,32].

Discussion of Imaging Modalities by Variant

Variant: Renal cell carcinoma staging

Staging of primary tumor

Preoperative imaging can provide important staging and anatomic information to the surgeon. Both CT and MRI are equally accurate in staging of the primary tumor [33,34]. It is important to be aware that a change in the pathologic stage of malignant renal neoplasms postoperatively is common, mainly due to disparities in radiographic and pathologic size or the pathologic presence of perinephric or renal sinus fat invasion that is not easily detected on imaging [35-37]. RCC can be multifocal. One of the important roles of preoperative imaging studies is also to look for synchronous primary tumors. Hence, it is important to obtain an adequately designed CT and MRI protocol that includes the nephrographic phase to optimize detectability and characterize small lesions.

Size of the primary tumor and degree of local invasion determines the T stage classification in the AJCC TNM staging system [8]. Tumors confined to the kidneys are staged as T1 or T2, depending on the size. Tumors <7 cm are staged as T1, with a further subclassification into T1a and T1b based on a cut-off of 4 cm. Tumors >7 cm in maximum diameter, confined to the kidneys, are staged T2. Extrarenal extension into the perinephric/renal sinus fat or renal vein is staged as T3a; extension of tumor thrombus into the inferior vena cava (IVC) is staged T3b or T3c. Adjacent organ involvement, including extension beyond the Gerota fascia or involvement of the ipsilateral adrenal gland, is T4 disease.

Perinephric tumor extension (T3a) is difficult to discriminate from nonspecific perinephric stranding due to edema, vascular engorgement, or fibrosis. High-resolution CT using thin sections appears to improve detection of perinephric infiltration, although false positives are common [33,34,38]. Breath-hold MRI showing lack of perinephric fat involvement is reported to have a high negative predictive value for no perinephric tumor invasion [39]. In a study of 73 RCCs, Roy et al [40] showed that the presence of a pseudocapsule on MRI had an accuracy of 93% for clear-cell carcinomas in separating T1/T2 tumors from T3a tumors.

Renal sinus fat invasion (T3a) is also difficult to accurately detect on CT [41]. It is considered the most common site for extrarenal extension of RCC [42,43]. The clinical significance of this finding is controversial. Several authors believe that the presence of renal sinus fat invasion heralds a poorer prognosis compared with perinephric fat invasion [44,45]. However, Margulis et al [46] found no significant difference in outcomes. Nevertheless, the presence of renal sinus fat invasion poses special challenges in planning nephron-sparing procedures; hence, special caution should be taken when evaluating these structures. Some urologists rely on intraoperative frozen sections, when available, to make these determinations. [47].

Direct contiguous spread to the adrenal gland is classified as T4. CT has a high sensitivity and nearly a 100% negative predictive value in detecting direct contiguous spread to the ipsilateral adrenal gland [22,48]. However, the positive predictive value of CT is lower, as it may be difficult to distinguish abutment from direct invasion.

The extent of venous invasion of tumor is an important factor in the T stage classification in the current TNM staging system. Tumor extension into segmental branches or the main renal vein is seen in approximately 20% of cases and has been reclassified as T3a in light of recent evidence that this group of patients tends to have a better prognosis compared with those with extension of tumor into the IVC, which is seen in up to 10% of patients [49-51]. Not only must the involvement of the renal veins and IVC be identified but the cephalad extent of the tumor must also be correctly assessed for preoperative planning. Depending on the level of the IVC thrombus, the surgeon may need to perform more extensive mobilization of the liver in order to obtain suprahepatic IVC access. An intra-atrial thrombus may require cardiac bypass. A thrombus limited to the renal vein ostium can be retracted back into the vein without the need to perform temporary ligation of the IVC and cavotomy. Rarely, transmural invasion of the caval wall might necessitate a graft placement. Therefore, accurate assessment of the extent of the caval thrombus is important. The prognostic significance of the extent of venous thrombus is still a topic of controversy, but recent evidence shows that supradiaphragmatic extension of an IVC thrombus heralds a poorer prognosis than does subdiaphragmatic extension [49,51,52].

Venous thrombus in the renal vein or IVC can usually be identified on the venous phase or delayed phase of the initial diagnostic CT. In cases where the findings are equivocal, MRI may be helpful. Tumor thrombus in the segmental branches of the renal vein may be more difficult to determine than thrombus in the main renal vein and IVC [41]. Both contrast-enhanced multidetector CT and MRI have equal sensitivity in detecting venous involvement, particularly in the main renal vein and the IVC [38,53]. Signs suggestive of renal vein or caval thrombus include filling defects, enlargement of the vessel, and rim enhancement. The pitfalls in CT occur with technically inadequate boluses of contrast media, motion, and flow artifact.

Due to its higher tissue contrast, noncontrast MRI has a higher sensitivity and specificity for detecting venous extension than does noncontrast CT. Pitfalls of MRI include the potential for large tumors to compress the vena cava and cause flow-related artifacts. Such artifacts can be reduced with appropriate saturation pulses. With bright-blood techniques, rapid or turbulent flow can also lead to artifacts. Diagnostic accuracy is improved with gadolinium-enhanced MR venography. The highest sensitivity and specificity in assessing venous involvement are achieved with a gradient-echo sequence [34,54]. Bland thrombus featuring a uniform signal intensity and lack of enhancement after gadolinium can be distinguished from tumor thrombus, which exhibits intermediate or high signal intensity, heterogeneous intensity, and, more reliably, the presence of small vessels. However, if a good-quality CT is obtained with adequate venous opacification, MRI is usually not needed. Invasion of the renal vein is better recognized on MRI studies. Diameter of the IVC and renal vein, presence of signal alterations in the vessel wall, flow around the tumor thrombus, and mobility in different phases are some of the signs that are useful [55,56].

Venous anomalies should be identified, specifically the presence of a retroaortic left renal vein or circumaortic left renal vein, as these have surgical implications. CT and MR angiograms can be incorporated in any staging study to determine any arterial or venous anomalies that may be helpful in surgical planning. US and color duplex US can be used to study venous invasion and venous anatomy, but this technique is of limited value in obese patients and in the presence of bowel gas, which interferes with the ability to image the renal vein–IVC junction. US is also highly dependent on the expertise of the operator.

Catheter angiography is insensitive for tumor thrombus. Its main roles are for preoperative embolization to control the renal artery in anticipation of a thrombectomy and for palliation of hematuria in inoperable tumors [57,58].

Contiguous invasion of the adrenal gland, liver, diaphragm, psoas muscles, pancreas, and bowel is seen in advanced T4 tumors and usually portends a poor prognosis. Both CT and MRI have poor positive predictive value for distinguishing invasion from mere abutment. However, CT offers a high negative predictive value in excluding direct contiguous invasion [22,48].

Including the pelvis in a routine staging examination is of limited value and is not likely to yield any significant results unless in rare instances of ectopic kidneys located in the pelvis. Two retrospective studies looking at a total of 519 staging CTs including both abdomen and pelvis reported that none of the pelvic CTs offered management-altering information not already known to the clinical team [59,60].

Nodal staging

As the current methodology for detecting lymph node metastases is based only on size, all imaging is suboptimal for N staging. Cross-sectional imaging criteria for diagnosing metastatic lymph nodes include a short-axis diameter of >1 cm and disruption of the normal lymph node architecture. However, based on this criterion, CT has a false-negative rate of about 10%, and nearly 50% of enlarged lymph nodes tend to be benign [61]. MR lymphography with iron oxide nanoparticles shows promise, but the agent is not yet available in the United States [62]. CT-guided aspiration biopsies are an alternative and can be performed if documenting nodal metastases impacts clinical management decisions.

Distant metastases

Distant metastases are most commonly seen in lungs, bone, liver, and brain. Chest imaging is important to RCC staging. Routine chest radiographs are considered adequate, but the routine use of chest CT is more controversial. The risk of pulmonary metastasis increases with the size of the primary tumor, and although universally accepted guidelines do not yet exist [63], chest CT is justified for larger primary tumors. When the chest radiograph is suspicious or positive, chest CT is useful for confirming or excluding metastases and defining the extent of metastatic disease.

Bone metastasis has been identified as an independent prognostic variable associated with poor survival in patients with metastatic RCC. In symptomatic patients who have advanced primary tumors or who have abnormal laboratory findings such as elevated alkaline phosphatase, a bone scan may be helpful to establish the diagnosis of bone metastasis [64].

Brain metastasis is seen in up to 17% of patients with metastatic RCC. Patients with acute neurological signs or symptoms should receive prompt MRI of the brain or a contrast-enhanced CT scan of the head. There is no evidence to justify routine use of brain MRI; however, it can be used to detect asymptomatic occult brain metastasis in patients with advanced RCC [65].

PET does not have an established role in the initial staging of renal cancer, in part due to the low avidity of metastatic RCC lesions. It may be difficult to detect primary renal cancers against the normal background of high activity in the kidneys on FDG-PET [66]. PET may be helpful for establishing metastatic disease in lesions detected by CT, MRI, or bone scan, and it can be used to detect unsuspected metastases in high-risk patients [67,68]. Although negative PET results cannot exclude metastatic disease, a positive PET scan should be considered highly suspicious due its high specificity.

Summary of Recommendations

- Contrast-enhanced multiphase CT scanning of the abdomen is the diagnostic modality of choice for staging a primary renal tumor. MRI of the abdomen is a suitable substitute when the patient cannot undergo contrast-enhanced CT. If the status of the renal veins and IVC cannot be determined on CT, contrast-enhanced multiphase 3-D MR venography can be performed.
- CT of the chest should be used to detect pulmonary metastasis in patients with large or locally advanced tumors. Chest radiography may be sufficient in patients with small primary tumors.
- In patients with suspicion for metastatic disease based on symptoms, other sites of metastases, or abnormal laboratory findings, brain MRI and bone scans can be performed.

Summary of Evidence

Of the 68 references cited in the *ACR Appropriateness Criteria® Renal Cell Carcinoma Staging* document, 56 are categorized as diagnostic references including 1 well designed study, 12 good quality studies, and 24 quality studies that may have design limitations. Additionally, 10 references are categorized as therapeutic references including 5 good quality studies. There are 24 references that may not be useful as primary evidence. There are 2 references that are meta-analysis studies.

The 68 references cited in the *ACR Appropriateness Criteria® Renal Cell Carcinoma Staging* document were published from 1990-2015.

While there are references that report on studies with design limitations, 18 well designed or good quality studies provide good evidence.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the *ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#)* document.

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊛	<0.1 mSv	<0.03 mSv
⊛⊛	0.1-1 mSv	0.03-0.3 mSv
⊛⊛⊛	1-10 mSv	0.3-3 mSv
⊛⊛⊛⊛	10-30 mSv	3-10 mSv
⊛⊛⊛⊛⊛	30-100 mSv	10-30 mSv

*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

Supporting Documents

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65(1):5-29.
2. King SC, Pollack LA, Li J, King JB, Master VA. Continued Increase in Incidence of Renal Cell Carcinoma, Especially in Young Patients and High Grade Disease: United States 2001 to 2010. *J Urol*. 2014;191(6):1665-1670.
3. National Cancer Data Base (NCDB). <http://www.facs.org/cancer/ncdb/index.html>. Accessed September 30, 2015.
4. Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. *Urol Oncol*. 2003;21(1):39-44.
5. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. *Curr Treat Options Oncol*. 2003;4(5):385-390.
6. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. *AJR Am J Roentgenol*. 2007;189(2):360-370.
7. Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. *J Urol*. 2009;181(2):506-511.
8. Edge SB, Byrd DR, Compton CC, et al. *AJCC Cancer Staging Manual (7th Edition)*. New York, NY: Springer; 2010.
9. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. *J Urol*. 2005;173(6):1889-1892.
10. Nese N, Paner GP, Mallin K, Ritchey J, Stewart A, Amin MB. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. *Ann Diagn Pathol*. 2009;13(1):1-8.
11. Yoo C, Song C, Hong JH, Kim CS, Ahn H. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. *J Urol*. 2008;180(2):486-491; discussion 491.
12. Park WH, Eisen T. Prognostic factors in renal cell cancer. *BJU Int*. 2007;99(5 Pt B):1277-1281.
13. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. *J Urol*. 2008;179(6):2146-2151; discussion 2151.
14. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol*. 2005;173(1):48-51.
15. Suzuki K, Nishiyama T, Hara N, Akazawa K, Takahashi K. Kattan postoperative nomogram for renal cell carcinoma: predictive accuracy in a Japanese population. *Int J Urol*. 2011;18(3):194-199.
16. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*. 2013;499(7456):43-49.

17. Joseph RW, Kapur P, Serie DJ, et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. *Cancer*. 2014;120(7):1059-1067.
18. Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. *Lancet Oncol*. 2013;14(2):159-167.
19. Klatte T, Patard JJ, de Martino M, et al. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. *J Urol*. 2008;179(5):1719-1726.
20. Guethmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B. Metastatic potential in renal cell carcinomas ≤ 7 cm: Swedish Kidney Cancer Quality Register data. *Eur Urol*. 2011;60(5):975-982.
21. Steffens S, Junker K, Roos FC, et al. Small renal cell carcinomas--how dangerous are they really? Results of a large multicenter study. *Eur J Cancer*. 2014;50(4):739-745.
22. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrin A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. *J Urol*. 2000;163(4):1090-1095; quiz 1295.
23. Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). *Cancer*. 2008;112(8):1827-1834.
24. Kuhn MJ, Hammer GM, Swenson LC, Youssef HT, Gleason TJ. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. *Comput Med Imaging Graph*. 1994;18(5):391-399.
25. Dalla-Palma L, Pozzi-Mucelli R. Problematic renal masses in ultrasonography and computed tomography. *Clin Imaging*. 1990;14(2):83-98.
26. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. *Radiology*. 2006;238(1):264-271.
27. Fuccio C, Ceci F, Castellucci P, et al. Restaging clear cell renal carcinoma with 18F-FDG PET/CT. *Clin Nucl Med*. 2014;39(6):e320-324.
28. Martinez de Llano SR, Delgado-Bolton RC, Jimenez-Vicioso A, et al. [Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma]. *Rev Esp Med Nucl*. 2007;26(1):19-29.
29. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. *BJU Int*. 2009;103(5):615-619.
30. Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. *Cancer Imaging*. 2012;12:464-474.
31. Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. *J Nucl Med*. 2015;56(2):222-228.
32. Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. *J Nucl Med*. 2014;55(7):1054-1061.
33. Hallscheidt PJ, Bock M, Riedasch G, et al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologic correlation. *J Comput Assist Tomogr*. 2004;28(3):333-339.
34. Walter C, Kruessell M, Gindele A, Brochhagen HG, Gossmann A, Landwehr P. Imaging of renal lesions: evaluation of fast MRI and helical CT. *Br J Radiol*. 2003;76(910):696-703.
35. Goel MC, Mohammadi Y, Sethi AS, Brown JA, Sundaram CP. Pathologic upstaging after laparoscopic radical nephrectomy. *J Endourol*. 2008;22(10):2257-2261.
36. Jeffery NN, Douek N, Guo DY, Patel MI. Discrepancy between radiological and pathological size of renal masses. *BMC Urol*. 2011;11:2.
37. Liu Y, Song T, Huang Z, Zhang S, Li Y. The accuracy of multidetector Computed Tomography for preoperative staging of renal cell carcinoma. *Int Braz J Urol*. 2012;38(5):627-636.
38. Catalano C, Fraioli F, Laghi A, et al. High-resolution multidetector CT in the preoperative evaluation of patients with renal cell carcinoma. *AJR Am J Roentgenol*. 2003;180(5):1271-1277.
39. Kamel IR, Hochman MG, Keogan MT, et al. Accuracy of breath-hold magnetic resonance imaging in preoperative staging of organ-confined renal cell carcinoma. *J Comput Assist Tomogr*. 2004;28(3):327-332.

40. Roy C, Sr., El Ghali S, Buy X, et al. Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study. *AJR Am J Roentgenol*. 2005;184(1):113-120.
41. Hallscheidt P, Wagener N, Gholipour F, et al. Multislice computed tomography in planning nephron-sparing surgery in a prospective study with 76 patients: comparison of radiological and histopathological findings in the infiltration of renal structures. *J Comput Assist Tomogr*. 2006;30(6):869-874.
42. Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. *Am J Surg Pathol*. 2004;28(12):1594-1600.
43. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. *Cancer*. 2007;109(12):2439-2444.
44. Bertini R, Roscigno M, Freschi M, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. *J Urol*. 2009;181(5):2027-2032.
45. Thompson RH, Leibovich BC, Chevillet JC, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? *J Urol*. 2005;174(4 Pt 1):1218-1221.
46. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. *J Urol*. 2007;178(5):1878-1882.
47. Sidana A, Donovan JF, Gaitonde K. Surgeons' preferences and practice patterns regarding intraoperative frozen section during partial nephrectomy. *Urol Oncol*. 2014;32(6):864-868.
48. Sawai Y, Kinouchi T, Mano M, et al. Ipsilateral adrenal involvement from renal cell carcinoma: retrospective study of the predictive value of computed tomography. *Urology*. 2002;59(1):28-31.
49. Ficarra V, Galfano A, Guille F, et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. *J Urol*. 2007;178(2):418-424; discussion 423-414.
50. Moch H, Artibani W, Delahunt B, et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. *Eur Urol*. 2009;56(4):636-643.
51. Moynadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? *J Urol*. 2004;171(2 Pt 1):598-601.
52. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? *J Urol*. 2004;171(2 Pt 1):588-591.
53. Hallscheidt PJ, Fink C, Haferkamp A, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. *J Comput Assist Tomogr*. 2005;29(1):64-68.
54. Ergen FB, Hussain HK, Caoili EM, et al. MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: comparison with surgical and pathologic staging. *AJR Am J Roentgenol*. 2004;182(1):217-225.
55. Aslam Sohaib SA, Teh J, Nargund VH, Lumley JS, Hendry WF, Reznik RH. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging. *J Urol*. 2002;167(3):1271-1275.
56. Zini L, Destrieux-Garnier L, Leroy X, et al. Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. *J Urol*. 2008;179(2):450-454; discussion 454.
57. Rodriguez Carvajal R, Orgaz A, Leal JI, et al. Renal embolization and nephrectomy in a single surgical act in high-risk renal tumor pathology. *Ann Vasc Surg*. 2011;25(2):222-228.
58. Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. *BJU Int*. 2003;92(3):240-244.
59. Fielding JR, Aliabadi N, Renshaw AA, Silverman SG. Staging of 119 patients with renal cell carcinoma: the yield and cost-effectiveness of pelvic CT. *AJR Am J Roentgenol*. 1999;172(1):23-25.
60. Khaitan A, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M. Is there a need for pelvic CT scan in cases of renal cell carcinoma? *Int Urol Nephrol*. 2002;33(1):13-15.
61. Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. *World J Urol*. 2004;22(5):307-315.
62. Guimaraes AR, Tabatabaei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotropic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. *Urology*. 2008;71(4):708-712.

63. Hsu RM, Chan DY, Siegelman SS. Small renal cell carcinomas: correlation of size with tumor stage, nuclear grade, and histologic subtype. *AJR Am J Roentgenol*. 2004;182(3):551-557.
64. Santini D, Procopio G, Porta C, et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. *PLoS One*. 2013;8(12):e83026.
65. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. *Cancer*. 2008;113(7):1641-1648.
66. Ozulker T, Ozulker F, Ozbek E, Ozpacaci T. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. *Nucl Med Commun*. 2011;32(4):265-272.
67. Kang DE, White RL, Jr., Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. *J Urol*. 2004;171(5):1806-1809.
68. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. *J Clin Oncol*. 2003;21(21):3995-4000.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.